SAN DIEGO–(BUSINESS WIRE<\/a>)– \n***\n<\/p>\n \nJuly 1, 2021\n<\/p>\n \nDear Stockholders,\n<\/p>\n \nThe Board of Directors (the “Board”) appreciates your continued investment in Adamis Pharmaceuticals Corporation (“Adamis” or the “Company” or \u201cwe\u201d). The Board also appreciates the feedback that many stockholders have provided in recent weeks. As we work to position Adamis for long-term success, please trust that this input will be carefully assessed and factored into our go-forward plans.\n<\/p>\n \nWe are writing to you today to once again urge you to vote to re-elect all five members of the Board at the Company\u2019s upcoming Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d) on July 16, 2021. In our view, maintaining boardroom continuity can help the Company achieve the following:\n<\/p>\n Based on our decades of collective experience in the biotechnology and pharmaceutical sectors, we firmly believe that Adamis is nearing a promising inflection point<\/span><\/b>. We contend it is not the time to deviate from these priorities. The progress we are beginning to catalyze for SYMJEPI\u00ae, ZIMHI\u2122 and now Tempol stems from months and years of planning and work. This is the time to remain focused on \u2013 not pull back from \u2013 the efforts we are undertaking.\n<\/p>\n Unfortunately, Jerald A. Hammann \u2013 a holder of 1,000 shares with no industry expertise, no public company experience and no articulated plan \u2013 is trying to remove and replace 80% of your Board. <\/span><\/b>We believe a more effective way for stockholders to communicate concerns is to write to the Company directly instead of seemingly throwing away a vote on Mr. Hammann\u2019s misguided effort.\n<\/p>\n \nWe urge stockholders not to be misled for a number of reasons, including:\n<\/p>\n \nWe hope stockholders recognize that supporting Mr. Hammann\u2019s misguided campaign would be akin to taking what we believe is a major risk. Rather than support a litigious stockholder that is waging a costly and distracting battle with the Company, we urge you to reject his efforts by voting to re-elect your current Board.\n<\/p>\n \nOnce again, we thank you for your investment in Adamis. We firmly believe that the Company is on the right path now that we have tangible pipeline momentum. Vote on the WHITE<\/span><\/b>proxy card<\/b> to elect our full five-member slate and help us sustain the Company\u2019s progress.\n<\/p>\n \nSincerely,\n<\/p>\n \nThe Adamis Board of Directors\n<\/p>\n \n***\n<\/p>\n PROTECT YOUR INVESTMENT IN ADAMIS \u2013 PLEASE SIGN, DATE AND PROMPTLY RETURN THE WHITE<\/span> PROXY CARD.<\/b><\/p>\n The Board urges you to carefully consider the information contained in the Company\u2019s proxy materials and cast your vote on the WHITE proxy card.<\/b><\/p>\n CONTACT THE COMPANY\u2019S PROXY SOLICITOR AT INFO@SARATOGAPROXY.COM<\/a> OR (888) 368-0379 IF<\/b>YOU HAVE ANY QUESTIONS REGARDING THE ANNUAL MEETING OR HOW TO VOTE.<\/b><\/p>\n ***<\/b><\/p>\n About Adamis Pharmaceuticals<\/span><\/b><\/p>\n \nAdamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company\u2019s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis\u2019 naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company\u2019s subsidiary, US Compounding Inc. (\u201cUSC\u201d), compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com<\/a>.\n<\/p>\n Forward Looking Statements<\/span><\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and\/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the Company\u2019s beliefs concerning the safety and effectiveness of Tempol and the Company\u2019s other product candidates; the timing of commencement or completion of any studies or trials relating to Tempol and the availability of funding for studies or trials; the results of any studies or trials that the Company may conduct relating to Tempol; the Company\u2019s ability to successfully commercialize the products and product candidates described in this press release, itself or through commercialization partners, and the Company\u2019s beliefs concerning the commercial success of its products; future regulatory actions relating to the Company\u2019s New Drug Application (\u201cNDA\u201d) relating to its ZIMHI product; the Company\u2019s beliefs concerning the benefits, enforceability, and extent of intellectual property protection afforded by patents and patent applications that it owns or has licensed and its rights under applicable license agreements, and its ability to enforce its patents and other intellectual property rights against third parties; the Company\u2019s expectations concerning future growth; expectations and statements about the Company\u2019s strategies, objectives, future goals and achievements; and other statements concerning our future operations, activities and financial results. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis\u2019 actual results to be materially different from the results anticipated by such forward-looking statements. There can be no assurances regarding the outcome of trials or studies relating to Tempol or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. There can be no assurances that future sales of SYMJEPI will meet our expectations. There can be no assurances regarding the timing or outcome of the FDA\u2019s review of our resubmitted NDA relating to ZIMHI, or that the Company will be able to successfully take any actions or develop any additional information that the FDA may require in connection with its review of the resubmitted NDA for ZIMHI. There can be no assurances that the FDA will consider the Company\u2019s responses included in the resubmitted NDA relating to ZIMHI as satisfactory, or that the product will be able to compete successfully in the market if approved and launched. The Company may not achieve one or more of the future goals described in the press release either within the anticipated time periods or at all. In addition, as previously disclosed, each of the Company and USC previously received a subpoena from the U.S. Attorney\u2019s Office for the Southern District of New York issued in connection with a criminal investigation. Accordingly, all forward-looking statements are subject to the outcome of this investigation, as well as the related investigation being conducted by the Company\u2019s Audit Committee. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis\u2019 filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2020 and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http:\/\/www.sec.gov<\/a>.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210701005491\/en\/<\/a><\/span><\/p>\n \nSaratoga Proxy Consulting
\nAdamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders.\n<\/p>\n\n
\n
\n
<\/p>\n
\n
John Ferguson \/ Ann Marie Mellone, 212-257-1311
\n
jferguson@saratogaproxy.com<\/a> \/ amellone@saratogaproxy.com
\n<\/a><\/p>\n